These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33173529)

  • 1.
    Guo Q; Feng X; Zhou Y
    Front Genet; 2020; 11():1020. PubMed ID: 33173529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
    Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel loop-mediated isothermal amplification-based genotyping method and its application for identifying proprotein convertase subtilisin/kexin type 9 variants in familial hypercholesterolemia.
    Hamasaki M; Hosaka N; Freeman LA; Sato M; Hara K; Remaley AT; Kotani K
    Biochim Biophys Acta Gen Subj; 2022 Feb; 1866(2):130063. PubMed ID: 34848321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Hori M; Ohta N; Takahashi A; Masuda H; Isoda R; Yamamoto S; Son C; Ogura M; Hosoda K; Miyamoto Y; Harada-Shiba M
    Atherosclerosis; 2019 Oct; 289():101-108. PubMed ID: 31491741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia.
    Li B; Hao PP; Zhang Y; Yin RH; Kong QZ; Cai XJ; Zhao Z; Qi JN; Li Y; Xiao J; Wang F; Yi W; Ji XP; Su GH
    Oncotarget; 2017 May; 8(18):30455-30463. PubMed ID: 27458166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia.
    Di Taranto MD; Benito-Vicente A; Giacobbe C; Uribe KB; Rubba P; Etxebarria A; Guardamagna O; Gentile M; Martín C; Fortunato G
    Sci Rep; 2017 Nov; 7(1):15282. PubMed ID: 29127338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
    Maxwell KN; Breslow JL
    Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Diagnosis of Familial Hypercholesterolemia in Asia.
    Huang CC; Charng MJ
    Front Genet; 2020; 11():833. PubMed ID: 32793292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portuguese Familial Hypercholesterolemia Study: presentation of the study and preliminary results.
    Bourbon M; Rato Q;
    Rev Port Cardiol; 2006 Nov; 25(11):999-1013. PubMed ID: 17274457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience.
    Galema-Boers AMH; Lenzen MJ; Sijbrands EJ; Roeters van Lennep JE
    J Clin Lipidol; 2017; 11(3):674-681. PubMed ID: 28506389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.